Jeil Pharmaceutical Co.,Ltd (KRX:271980)
South Korea · Delayed Price · Currency is KRW 13,730
-220 (-1.58%)
Apr 2, 2026, 3:30 PM KST
KRX:271980 Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 23,384 | -29,968 | 5,005 | -13,091 | -12,473 |
Depreciation & Amortization | 12,317 | 11,297 | 9,767 | 8,886 | 9,133 |
Loss (Gain) From Sale of Assets | -12.08 | -7.97 | -0.53 | -9.99 | -30 |
Asset Writedown & Restructuring Costs | - | 478.3 | - | - | -607.15 |
Loss (Gain) From Sale of Investments | -1,091 | -359.57 | 201.1 | -2,065 | -189.64 |
Loss (Gain) on Equity Investments | -15,493 | -586.8 | -815.1 | 142.25 | -1,801 |
Stock-Based Compensation | 696.53 | 1,026 | 578.03 | 472.48 | 163.17 |
Provision & Write-off of Bad Debts | 682.28 | -1,041 | -2,096 | -370.58 | 1,626 |
Other Operating Activities | 10,328 | 36,147 | 3,069 | 6,044 | 8,663 |
Change in Accounts Receivable | 22,145 | -8,235 | -10,856 | -7,984 | 10,157 |
Change in Inventory | 359.54 | 369.35 | -10,575 | 3,562 | 6,334 |
Change in Accounts Payable | -45,595 | -10,390 | -7,620 | -1,664 | 9,625 |
Change in Other Net Operating Assets | -13,410 | 4,483 | 8,362 | -9,069 | -11,498 |
Operating Cash Flow | -5,690 | 3,213 | -4,981 | -15,147 | 19,100 |
Capital Expenditures | -8,032 | -4,278 | -6,097 | -11,085 | -5,344 |
Sale of Property, Plant & Equipment | 12.2 | 8.35 | 87.64 | 10 | - |
Sale (Purchase) of Intangibles | -1,045 | -2,335 | -3,436 | -5,873 | 91.43 |
Investment in Securities | -6,272 | -1,313 | -2,524 | 1,898 | -845.47 |
Other Investing Activities | - | 620.43 | 51.01 | 126.46 | 60.95 |
Investing Cash Flow | -15,337 | -7,297 | -11,919 | -12,924 | -8,037 |
Short-Term Debt Issued | 27,487 | 6,228 | 24,196 | 16,410 | - |
Total Debt Issued | 27,487 | 6,228 | 24,196 | 16,410 | - |
Short-Term Debt Repaid | - | - | - | - | -6,253 |
Long-Term Debt Repaid | -10,157 | -2,199 | -4,702 | -7,448 | -8,343 |
Total Debt Repaid | -10,157 | -2,199 | -4,702 | -7,448 | -14,596 |
Net Debt Issued (Repaid) | 17,331 | 4,029 | 19,494 | 8,962 | -14,596 |
Repurchase of Common Stock | - | - | - | -396.98 | -810.02 |
Dividends Paid | - | -728.38 | -728.38 | -947.74 | -1,022 |
Other Financing Activities | -280.72 | 19,762 | -0 | 26,001 | 27,498 |
Financing Cash Flow | 17,050 | 23,063 | 18,766 | 33,618 | 11,069 |
Foreign Exchange Rate Adjustments | -625 | 1,506 | -321.57 | -63.8 | -62.04 |
Miscellaneous Cash Flow Adjustments | - | - | - | -0 | -0 |
Net Cash Flow | -4,601 | 20,485 | 1,545 | 5,483 | 22,070 |
Free Cash Flow | -13,722 | -1,065 | -11,077 | -26,232 | 13,756 |
Free Cash Flow Margin | -2.42% | -0.15% | -1.52% | -3.63% | 1.96% |
Free Cash Flow Per Share | -941.83 | -73.10 | -760.21 | -1799.81 | 941.63 |
Cash Interest Paid | 4,281 | 4,183 | 4,255 | 1,805 | 921.03 |
Cash Income Tax Paid | 9,134 | 2,103 | 1,643 | -877.05 | 3,540 |
Levered Free Cash Flow | -22,192 | -33,199 | 2,881 | 4,052 | 20,240 |
Unlevered Free Cash Flow | -19,446 | -30,039 | 6,652 | 5,933 | 21,469 |
Change in Working Capital | -36,501 | -13,771 | -20,689 | -15,155 | 14,617 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.